News

CLINUVEL
Posted by CLINUVEL
August 23, 2022

CLINUVEL Communiqué IV

Melbourne, Australia, 23 August 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
August 5, 2022

Chair's Letter

In my first letter to you for 2022 I provide updates on...

Read More
CLINUVEL
Posted by CLINUVEL
July 28, 2022

PRÉNUMBRA® for stroke

Melbourne, Australia, 28 July 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
July 25, 2022

Appendix 4C & Activity Report

CLINUVEL PHARMACEUTICALS LTD today released its Appendix 4C – Quarterly Cashflow Report...

Read More
CLINUVEL
Posted by CLINUVEL
July 22, 2022

CLINUVEL Kommuniqué III

Seit dem News Communiqué II vom 31. März 2022 hat das Unternehmen...

Read More
CLINUVEL
Posted by CLINUVEL
June 23, 2022

Change of Director’s Interest Notice

Melbourne, Australia, 23 June 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
June 23, 2022

CLINUVEL Communiqué III

Since News Communiqué II on 31 March 2022, the Company has reported...

Read More
CLINUVEL
Posted by CLINUVEL
June 14, 2022

Change of Director’s Interest Notice

Melbourne, Australia, 14 June 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
June 14, 2022

Notice of ceasing to be a substantial holder

Melbourne, Australia, 14 June 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
June 10, 2022

Jeffries Healthcare Conference June 2022

CLINUVEL's Head of Investor Relations, Malcolm Bull, presents to the Jeffries Healthcare...

Read More